Literature DB >> 11746512

Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts.

F F Safadi1, J Xu, S L Smock, M C Rico, T A Owen, S N Popoff.   

Abstract

Osteoblast development is a complex process involving the expression of specific growth factors and regulatory proteins that control cell proliferation, differentiation, and maturation. In this study, we used the rat mutation, osteopetrosis (op), to examine differences in skeletal gene expression between mutant op and normal littermates. Total RNA isolated from long bone and calvaria was used as a template for mRNA differential display. One of many cDNAs that were selectively expressed in either normal or mutant bone was cloned and sequenced and found to share some homology to the human nmb and Pmel 17 genes. This novel cDNA was named osteoactivin. Osteoactivin has an open reading frame of 1716 bp that encodes a protein of 572 amino acids with a predicted molecular weight of 63.8 kD. Protein sequence analysis revealed the presence of a signal peptide and a cleavage site at position 23. The protein also has thirteen predicted N-linked glycosylation sites and a potential RGD integrin recognition site at position 556. Northern blot analysis confirmed that osteoactivin was 3- to 4-fold overexpressed in op versus normal bone. RT-PCR analysis showed that osteoactivin is most highly expressed in bone compared with any of the other non-osseous tissues examined. In situ hybridization analysis of osteoactivin in normal bone revealed that it is primarily expressed in osteoblasts actively engaged in bone matrix production and mineralization. In primary rat osteoblast cultures, osteoactivin showed a temporal pattern of expression being expressed at highest levels during the later stages of matrix maturation and mineralization and correlated with the expression of alkaline phosphatase and osteocalcin. Our findings show that osteoactivin expression in bone is osteoblast-specific and suggest that it may play an important role in osteoblast differentiation and matrix mineralization. Furthermore, osteoactivin overexpression in op mutant bone may be secondary to the uncoupling of bone resorption and formation resulting in abnormalities in osteoblast gene expression and function. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746512     DOI: 10.1002/jcb.1259

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  60 in total

1.  A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats.

Authors:  Sarah E Nichols; Dawn C Harper; Joanne F Berson; Michael S Marks
Journal:  J Invest Dermatol       Date:  2003-10       Impact factor: 8.551

2.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

3.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

4.  Generation and functional characterization of MDSC-like cells.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Jonas Schulte-Schrepping; Julia Friederike Andrea Wolff; Kathrin Klee; Thomas Ulas; Niklas Arndt Schmacke; Solveig Nora Daecke; Kati Riethausen; Joachim L Schultze; Peter Brossart
Journal:  Oncoimmunology       Date:  2017-02-23       Impact factor: 8.110

5.  Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro.

Authors:  Samir M Abdelmagid; Joyce Y Belcher; Fouad M Moussa; Suzanne L Lababidi; Gregory R Sondag; Kimberly M Novak; Afif S Sanyurah; Nagat A Frara; Roshanak Razmpour; Fabiola E Del Carpio-Cano; Fayez F Safadi
Journal:  Am J Pathol       Date:  2014-01-23       Impact factor: 4.307

6.  Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.

Authors:  Toshihiko Hoashi; Shinichi Sato; Yuji Yamaguchi; Thierry Passeron; Kunihiko Tamaki; Vincent J Hearing
Journal:  FASEB J       Date:  2010-01-07       Impact factor: 5.191

7.  Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.

Authors:  Madeleine V Pahl; Nosratola D Vaziri; Jun Yuan; Sharon G Adler
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

8.  Identification of cell surface markers to differentiate rat endothelial and fibroblast cells using lectin arrays and LC-ESI-MS/MS.

Authors:  Ji Eun Lee; Shama P Mirza; Daniela N Didier; Mark Scalf; Michael Olivier; Andrew S Greene; Lloyd M Smith
Journal:  Anal Chem       Date:  2008-09-27       Impact factor: 6.986

Review 9.  Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.

Authors:  Kevin M Budge; Matthew L Neal; Jason R Richardson; Fayez F Safadi
Journal:  Mol Neurobiol       Date:  2017-08-30       Impact factor: 5.590

10.  The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses.

Authors:  Jin-Sung Chung; Makoto Bonkobara; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.